Full Press Release Details
InspireMD to Host Conference Call and
Webinar and to Discuss Recently
Released Results of CGuard CARENET Trial on September 24th
CARENET Trial data presented at the
Transcatheter Cardiovascular Therapeutics (TCT)
conference, September 16, 2014, showed 0% MACE at 30 Days
Josh Jennings, MD, Senior Research Analyst at Cowen & Company,
will moderate a panel discussion featuring one of the Principal Investigators (PIs) of the CARENET trial, Professor Piotr Musialek,
from Jagiellonian University Medical College at John Paul II Hospital, in Krakow, Poland. The discussion will be followed by a
question and answer session.
The webinar will be available on the Investor Relations section
of the Company's website at http://www.inspire-md.com/site_en/for-investors/ . To participate by telephone, participants
should call (877) 407-0789 (United States) or (201) 689-8562 (International) and request the InspireMD call. A digital replay
of the webinar will be available for 30 days after the event.
The discussion will focus on the clinical benefits that the
MicroNetTM covered CGuard may offer patients undergoing carotid artery stenting compared to existing treatments
Findings from The CARENET trial, which recruited a total of
30 patients, include:
CGuard EPS is CE Mark approved. CGuard EPS, however, is not
approved for sales in the U.S. by the U.S. Food and Drug Administration at this time.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary
MGuard with MicroNetTM technology to make its products the industry standard for embolic protection and to provide
a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow
and major adverse cardiac events.
InspireMD intends to pursue applications
of this MicroNet technology in coronary, carotid (CGuardTM) and peripheral artery procedures. InspireMD's common stock
is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory
reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product
components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that
such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-KT and its Quarterly Reports
on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com
Phone: KCSA Strategic Communications